Aldin Velic, Vice President & General Manager, Nelipak Asia-Pacific
There is a moment that comes up repeatedly in conversations with MedTech engineering and regulatory teams across Asia-Pacific. The device is largely settled, and the team is moving toward design freeze. And someone raises the packaging question, often framed as: how quickly can we sort this out before we file?
That framing is understandable. Packaging feels like infrastructure. Necessary, but secondary. But by the time most teams ask the question, the decisions that determine their compliance trajectory, their validation costs, and their time to market have already been made. The geometry of the device, the sterilization method and the markets they intend to enter, impacts what is still possible on the packaging side. What looks like a late-stage task is a set of upstream decisions made by default.
The companies that navigate multi-market compliance well, do something different. They bring packaging into the conversation early, not as a procurement function, but as a design discipline with direct regulatory implications.
Considering packaging early on
When a MedTech company considers packaging in the R&D stage, the first questions are not about materials or tooling costs, but about the key requirements. Which markets should be prioritized for launch, and which ones follow? What sterilization method does the device require, and has that been validated against the intended packaging system? What does distribution look like, are there humidity considerations, cold chain requirements, or drop and vibration exposures the sterile barrier needs to withstand?
These questions matter because ISO 11607, the international baseline standard for sterile barrier systems, requires validated evidence across seal integrity, distribution simulation and accelerated aging. The validation package that regulators expect is substantial, and the regulatory cost of a late packaging decision is real and measurable. When a material or configuration needs to change mid-development, revalidation can add time and cost. It is far easier and cost-effective to design toward it from the beginning than retrofitting to a packaging configuration chosen for cost or convenience. For early-stage companies, that is often the difference between meeting a regulatory submission window or missing it entirely.
Multi-market compliance has become materially more complex
The regulatory environment that Asia-Pacific MedTech companies are navigating has shifted significantly in the past two years, and the packaging implications are underappreciated. Designing for multi-market compliance from the outset impacts the process and economics considerably.
The EU Medical Device Regulation (MDR) raised the evidentiary bar on packaging accountability in ways that go well beyond the old Medical Devices Directive. Under Annex II and III requirements, manufacturers now need verifiable documentation of packaging system suitability and sterilization compatibility as part of the technical file, including distribution simulation, seal integrity and shelf-life validation. Many companies selling into Europe are still working through the gap between their legacy documentation and what MDR now demands.
In the United States, the FDA finalized its Quality Management System Regulation in early 2024 (21 CFR Part 820 QMSR), which came into effect in February 2026 and aligns US requirements more closely with ISO 13485, the international standard for quality management systems in the medical device industry. Companies selling into both markets need to run parallel documentation and validation upgrade cycles simultaneously.
For Asia-Pacific specifically, the picture is more fragmented, but no less demanding. The ASEAN Medical Device Directive is driving harmonization across ten member states with varying levels of implementation maturity. China’s National Medical Products Administration (NMPA) issued updated requirements for overseas manufacturers in January 2025. ISO 11607 is the common baseline, but each market has additional local requirements, and this is where companies consistently underestimate the complexity and timeline.
A sterile barrier system built with EU MDR, FDA QMSR, and APAC requirements in mind from day one requires rigorous validation effort at once. A system optimized for a single market and adapted later requires additional effort and cost, often at the worst possible moment in a product’s development cycle.
What Asia-Pacific based companies can now access
One of the structural gaps that has historically constrained MedTech innovation in Asia-Pacific is access to integrated technical development capability in the region. Teams had to engage with packaging partners remotely, across significant time zone and logistics gaps, or to build in-house capabilities that most early-to-mid stage companies cannot justify. Access to dedicated packaging design, prototyping, and validation support in Asia-Pacific changes that equation in a specific and practical way.
For early-stage companies that do not have a dedicated regulatory or packaging function internally, in-region capability compresses timelines meaningfully and removes risks that tend to surface at the wrong time. Design iterations that previously required international logistics and multi-week turnarounds can now happen at a very different cadence. For more established companies, the significance is in reducing dependence on a development process that was, by necessity, structured around geography rather than program timing.
The companies that get this right share a common pattern
MedTech companies that have navigated MDR and multi-market compliance successfully, treated packaging as a design input that carried regulatory weight from the beginning, not as a downstream deliverable. They identified their target markets early, and structured their validation architecture around the most demanding requirements rather than the most convenient one. And they engaged technical expertise when it could still influence the design and not just execute.
Beyond compliance, the opportunity in Asia-Pacific is real and it is growing. Rising incomes, expanding government healthcare investment, and a pipeline of innovative devices looking to reach multiple markets simultaneously are creating conditions where the ability to compress development timelines is a genuine commercial differentiator. The companies treating packaging strategy as part of their commercial strategy, not separate from it, are the ones reaching market faster, with fewer surprises, and with a compliance posture that holds under scrutiny.
That is not a packaging question. It is a business question. The packaging just happens to be where a lot of the answer lives.